ACALABRUT

Advanced Targeted Therapy for Leukemia and Lymphoma

ACALABRUT is a prescription-based targeted anticancer medicine containing Acalabrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor used for the treatment of various B-cell blood cancers, including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Mantle Cell Lymphoma (MCL). It is designed to specifically target abnormal B-cells by blocking BTK, a protein that plays a key role in the growth and survival of cancer cells.

Unlike conventional chemotherapy, ACALABRUT offers a precision medicine approach by targeting specific signaling pathways involved in cancer progression. This targeted mechanism helps slow the growth of cancer cells, delay disease progression, and improve long-term treatment outcomes while preserving healthy cells. ACALABRUT should only be used under the supervision of an experienced hematologist or oncologist.

Key Benefits of ACALABRUT

• Contains Acalabrutinib, a selective BTK inhibitor
• Used in the treatment of Chronic Lymphocytic Leukemia (CLL)
• Effective for Small Lymphocytic Lymphoma (SLL)
• Indicated for Mantle Cell Lymphoma (MCL)
• Helps slow the growth and spread of abnormal B-cells
• Provides targeted therapy with a precision medicine approach
• Convenient oral capsule formulation
• Supports long-term blood cancer management

Uses of ACALABRUT

ACALABRUT may be prescribed for the treatment of:

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Other B-cell malignancies as recommended by a hematologist or oncologist

Why Choose ACALABRUT?

ACALABRUT represents an advanced targeted therapy for patients with blood cancers. Its selective BTK inhibition helps provide effective treatment while minimizing damage to healthy cells. It is widely used in modern hematology and oncology for patients requiring precision treatment for leukemia and lymphoma.

Important Safety Information

• Prescription-only anticancer medicine.
• Use only under the supervision of a qualified hematologist or oncologist.
• Regular blood tests and clinical monitoring are recommended during treatment.
• Inform your doctor about any history of bleeding disorders, infections, liver disease, heart conditions, or ongoing medications before starting therapy.
• Do not stop taking the medicine without consulting your healthcare provider.
• Keep out of reach of children.